We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+3.56%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.89B
AUM Growth
+$345M
Cap. Flow
-$69.9M
Cap. Flow %
-2.42%
Top 10 Hldgs %
30.33%
Holding
133
New
31
Increased
28
Reduced
22
Closed
15

Top Buys

Rank Stock Value
1
QTTB icon
Q32 Bio
QTTB
+$97.6M
2
CNC icon
Centene
CNC
+$61.3M
3
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$51.5M
4
MLNT
Melinta Therapeutics, Inc. Common Stock
MLNT
+$41.1M
5
CVS icon
CVS Health
CVS
+$39.5M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$52.4M
2
GKOS icon
Glaukos
GKOS
+$51.5M
3
PODD icon
Insulet
PODD
+$41.5M
4
MCK icon
McKesson
MCK
+$38.1M
5
RVNC
Revance Therapeutics, Inc.
RVNC
+$35.8M

Sector Composition

Rank Sector Weight
1 Healthcare 74.89%
2 Financials 1.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALPN
76
DELISTED
Alpine Immune Sciences Inc
ALPN
$7.3M 0.25%
913,100
– –
NEOS
77
DELISTED
Neos Therapeutics, Inc
NEOS
$7.18M 0.25%
864,906
+119,139
+16% +$1.14M
ARMO
78
DELISTED
ARMO BioSciences, Inc. Common Stock
ARMO
$7.05M 0.24%
+188,525
New +$7.92M
BLUE
79
DELISTED
bluebird bio
BLUE
$7M 0.24%
3,165
-3,011
-49% -$7.66M
ALIM
80
DELISTED
Alimera Sciences
ALIM
$6.24M 0.22%
403,529
– –
MRTX
81
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$6.05M 0.21%
197,000
-178,000
-47% -$4.94M
STDY
82
DELISTED
SteadyMed Ltd
STDY
$4.61M 0.16%
1,418,787
– –
ALBO
83
DELISTED
Albireo Pharma Inc
ALBO
$3.91M 0.14%
+120,000
New +$4.04M
SRRA
84
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.65M 0.13%
44,122
+95
+0.2% +$10.8K
FOMX
85
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.46M 0.12%
674,002
+173,002
+35% +$1.04M
MNKD icon
86
MannKind Corp
MNKD
$1.24B
$3.38M 0.12%
+1,482,601
New +$3.99M
TARA icon
87
Protara Therapeutics
TARA
$230M
$3.06M 0.11%
30,622
– –
TCMD icon
88
Tactile Systems Technology
TCMD
$641M
$2.89M 0.1%
+91,020
New +$2.81M
HYPD
89
Hyperion DeFi Inc
HYPD
$42.3M
$2.75M 0.1%
+3,750
New +$2.72M
IFRX icon
90
InflaRx
IFRX
$270M
$2.55M 0.09%
88,500
-86,500
-49% -$2.28M
ARLZ
91
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$2.47M 0.09%
1,644,583
– –
TSRO
92
DELISTED
TESARO, Inc.
TSRO
$2.45M 0.08%
42,893
– –
ADVM
93
DELISTED
Adverum Biotechnologies
ADVM
$2.45M 0.08%
+42,200
New +$2.63M
VYGR icon
94
Voyager Therapeutics
VYGR
$189M
$2.21M 0.08%
117,647
– –
EGLT
95
DELISTED
Egalet Corporation
EGLT
$2.04M 0.07%
+3,239,237
New +$2.8M
RARX
96
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$2.03M 0.07%
382,700
+303,550
+384% +$2.17M
TLGT
97
DELISTED
Teligent, Inc
TLGT
$1.61M 0.06%
+47,900
New +$1.52M
TNDM icon
98
Tandem Diabetes Care
TNDM
$1.22B
$1.58M 0.05%
+318,000
New +$1.03M
HIND
99
Vyome Holdings
HIND
$15.2M
– –
0
– –
SCYX icon
100
SCYNEXIS
SCYX
$39.7M
$1.37M 0.05%
+12,750
New +$1.76M
1 2 3
4
5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q1 2018 Portfolio in Review

As of Q1 2018, Deerfield Management held 133 positions worth $2.89B, up 14% from $2.54B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Deerfield Management's Q1 2018 filing shows 31 new, 28 increased, 22 reduced and 15 closed positions. Its largest new stake was Q32 Bio: 290,391 shares worth $97.7M. The largest sale was DexCom, an estimated $52.4M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 79% a quarter earlier, followed by Financials.

  • Deerfield Management's largest Q1 2018 buy was Q32 Bio: 290,391 shares worth $97.7M.
  • Deerfield Management added most to MALLINCKRODT PUBLIC LIMITED COMPANY in Q1 2018, an estimated $51.5M increase.
  • Deerfield Management's biggest Q1 2018 reduction was DexCom, cutting an estimated $52.4M.
  • Deerfield Management fully exited Revance Therapeutics, Inc. in Q1 2018, selling an estimated $35.8M.
  • Deerfield Management's ten largest holdings make up 30% of its $2.89B portfolio in Q1 2018.
  • Deerfield Management opened 31 new positions and closed 15 in Q1 2018.
  • Deerfield Management's portfolio value rose 14% quarter-over-quarter to $2.89B.

Based on Deerfield Management's 13F filing for Q1 2018, filed 15 May 2018.